MediGene’s ‘Airbag’ Equity Deal Provides EndoTAG-1 Partnering Flexibility
This article was originally published in The Pink Sheet Daily
Executive Summary
Option lets the firm sell up to 25M Euros in new stock to YA Global over three-year period.
You may also be interested in...
Medigene Refills Its Early Pipeline By Buying Trianta Immunotherapies
For just under €10 million, Germany’s Medigene completes its restructuring with immunotherapy platform technologies that include dendritic cell vaccines, T-cell receptor based products and anti-T-cell monoclonal antibodies.
Patient Death Halts Phase I Trial For MediGene RA Candidate
Talked up as a potential blockbuster, RhuDex produced positive Phase IIa findings a month earlier.
MediGene Oncologic Imparts 30% Survival Advantage In Pancreatic Cancer Phase II
German firm also studies anti-angiogenesis drug in hormone-resistant breast cancer.